Data Integrity Problems Found at Indian Facility
FDA issued a warning letter to Srikem Laboratories Pvt. Ltd. for data integrity violations
On Nov. 8, 2016, FDA sent a warning letter to Srikem Laboratories Pvt. Ltd. detailing data integrity violations found during a December 2015 inspection of the company’s Navi Mumbai facility. Specifically, the company failed to properly document laboratory control records.
FDA stated in the letter that the company failed to include complete data from all laboratory tests. The agency wrote, “Your quality unit must review all pertinent analytical data when making batch release decisions in order to determine batch quality.”
Laboratory records were also found to be inconsistently dated. The company responded to the observation saying the discrepancies were due to software malfunctions, power outages, and personnel shift changes. In the warning letter, FDA stated, “your response is inadequate because you have not sufficiently explained how you are improving controls, notwithstanding these claimed sources of discrepancies, to ensure the reliability and accuracy of the data you rely on to evaluate the quality of your drugs.”
Because of the observed violations and the company’s response to those violations, FDA placed Srikem Laboratories Pvt. Ltd. on Import Alert 66-40 on July 6, 2016. The agency recommended the company perform a comprehensive investigation into the data inaccuracies, conduct a risk assessment of potential effects of the data integrity failures on product quality, and develop a management strategy that includes a corrective action and preventive action plan.
Source: FDA
Regeneron Treatment for Multiple Myeloma Gets Conditional Marketing Approval from EC
April 29th 2025The indication is specific to patients who have received at least three prior therapies, including a proteasome inhibitor, immunomodulatory agent, and anti-CD38 monoclonal antibody, and have demonstrated disease progression on the last therapy.
MHRA Approves GSK Therapy Combinations for Multiple Myeloma
April 21st 2025Belantamab mafodotin is approved in combination with bortezomib plus dexamethasone in patients who have had at least one prior therapy, and in combination with pomalidomide plus dexamethasone for those who have had a prior therapy including lenalidomide.
